OpenEye Scientific Software
9 Bisbee Court
About OpenEye Scientific Software
OpenEye Scientific is an industry leader in computational molecular design based on decades of delivering rapid, robust, and scalable software, toolkits, and technology and design services across the drug discovery process. Our scientific approach has focused on visualizing and analyzing the shape and electrostatics of molecular 3D structures to inform and guide the advancement of pharmaceuticals and biotechnology. Founded in 1997, OpenEye is a privately held company headquartered in Santa Fe, New Mexico, with offices in Boston, Massachusetts; Cologne, Germany; and Tokyo, Japan.
19 articles with OpenEye Scientific Software
OpenEye Scientific, an industry leader in computational molecular design, has named Dr. Giovanna Scapin as its newest addition to its Board of Directors.
OpenEye Scientific, developer of the world’s only cloud-native molecular design platform, Orion,™ announced today that it is among the first of only a handful of companies globally that have achieved Amazon Web Services (AWS) High Performance Computing (HPC) Competency status.
OpenEye Scientific Incorporates Mcule Compound Library in Orion™ Platform to Accelerate Screening of Molecules
OpenEye Scientific and Mcule – a leading online marketplace for drug discovery – today announced that OpenEye's Orion™ molecular design platform now can greatly enhance the ability to search and screen molecules through Mcule's purchasable compound library.
Sygnature Discovery Adopts OpenEye Scientific's Orion™ Platform to Strengthen Molecular Design Services
OpenEye Scientific and Sygnature Discovery – a world-leading integrated discovery and pre-clinical solutions provider – today announced the adoption of OpenEye's Orion™ platform to power Sygnature's computational efforts in molecular design drug discovery solutions.
Gigadock™ Functionality in Orion™ Molecular Design Platform Rapidly Identifies Novel Chemical Entities for GPCR Targets
OpenEye Scientific and Beacon Discovery today announced the rapid identification of two novel chemical entities and more than 30 potent hits for known G-Protein Coupled Receptor (GPCR) targets using Gigadock™ functionality in OpenEye’s Orion™ molecular design cloud platform.
OpenEye Scientific (OpenEye) and CHDI Foundation (CHDI) today announced a research collaboration to identify novel small-molecule therapeutics for Huntington’s disease (HD) utilizing Orion, OpenEye’s cloud-native molecular design platform.
Optibrium™ and OpenEye Scientific (OpenEye), leading providers of software and services for drug discovery, today announced that StarDrop™, Optibrium’s software for small molecule design, optimisation and data analysis, is now powered by OpenEye Scientific’s cheminformatics toolkits.
Redesign Science and OpenEye Scientific are pleased to announce that they have entered into a strategic partnership to integrate OpenEye's pioneering Orion computational platform into Redesign's drug discovery platform.
OpenEye Scientific Software, Inc.’s Partner pKaData Completes Conversion of IUPAC Books of Experimental pKa Values to Substructure Searchable Databases
OpenEye Scientific Software, Inc. Releases FastROCS 1.0 – Extremely Fast 3D Molecular Shape Comparison on NVIDIA Corporation Tesla GPUs
SZYBKI Enables Entropy Calculations in Various Environments, as Well as Several Other New Features, in the 1.5.0 Release of the Molecular Structure Optimization and Virtual Screening Application from OpenEye Scientific Software, Inc.
OpenEye Scientific Software, Inc. Releases New Versions of Its Ligand-Based Design Applications ROCS and EON
OpenEye Scientific Software, Inc. Release: ROCS Outperforms Docking for 3D Virtual Screening in Merck & Co., Inc. Study